News and Events March 2021: BioAegis CEO, Dr. Susan Levinson, appointed to BioNJ Board Read More » February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity Read More » November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator Read More » September 2020: BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia Read More » August 2020: Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity Read More » August 2020: BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More » « Previous Page1 … Page3 Page4 Page5 Page6 Next » March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More » March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference Learn More » Articles: Insights, intelligence and opinions from our experts. A Pioneering Biotech Promises to Revolutionize Medicine with a Human Protein that Boosts the Body’s Immune System BioAegis Therapeutics expects to unlock the healing powers of gelsolin and develop new treatments for disease. Host-directed Therapeutics for the Next Pandemic: What They Are and Why We'll Need Them by Dr. Lester Kobzik, Chief Scientific Advisor and Professor (emeritus) of Pathology at The Harvard Medical School Sepsis: The Hydra Within Us As Wallstreet Funding for Sepsis Research has Evaporated US Government Funding Picks Up the Slackby Steven Cordovano, Co-founder, VP Business Development Vaccines Alone Are Not The Answer The US is overlooking Covid’s main culprit — the threat that vaccines do not address.by Susan L. Levinson, PhD., Co-founder and CEO
February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity Read More »
November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator Read More »
September 2020: BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia Read More »
August 2020: Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity Read More »
August 2020: BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More »
March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More »